AI assistant
Sending…
MADRIGAL PHARMACEUTICALS, INC. — Director's Dealing 2012
Jul 3, 2012
30608_dirs_2012-07-03_07561f00-50ed-4f23-871f-d8a0b83c070b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: SYNTA PHARMACEUTICALS CORP (SNTA)
CIK: 0001157601
Period of Report: 2012-07-01
Reporting Person: KUFE DONALD W (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2012-07-01 | Common Stock | A | 7312 | — | Acquired | 7312 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2012-07-01 | Director Stock Option (Right to Buy) | $5.47 | A | 10000 | Acquired | 2022-07-01 | Common Stock (10000) | Direct |
Footnotes
F1: Represents a restricted stock grant subject to the Issuer's lapsing forfeiture right, which lapses as to 25% of the shares on each of September 30, 2012, December 31, 2012, March 31, 2013 and June 30, 2013, provided the Reporting Person continues to serve as director of the Issuer on such date.
F2: The option vests as to 25% of the shares on each of September 30, 2012, December 31, 2012, March 31, 2013 and June 30, 2013, provided the Reporting Person continues to serve as a director of the Issuer on such date.
More from MADRIGAL PHARMACEUTICALS, INC.
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
May 6
Annual Report
2026
Apr 28
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 2
Director's Dealing
2026
Feb 24
Annual Report
2026
Feb 19
Earnings Release
2026
Feb 19
Regulatory Filings
2026
Jan 30
Director's Dealing
2026
Jan 26